YahooOctober 7, 2026 at 4:00 AM NY20 Days Ago
This biotech stock is a top pick at Guggenheim
Investing.com-- Guggenheim named Zura Bio a top pick in the biotechnology sector, reiterating its Buy rating and $20 price target ahead of the company’s Phase II TibuSHIELD readout in hidradenitis suppurativa, expected in the fourth quarter of 2026.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
